Skip to content

Study · Randomized controlled trial · n = 100 · 2023

2 results

Medroxyprogesterone Acetate versus Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surge in hyper-responder women undergoing controlled ovarian stimulation for IVF/ICSI Cycles.

Tandulwadkar S, Gupta S, Singh A, Mishra S, Singhania S

JBRA assisted reproduction30 Mar 2023Cited by 4 (Europe PMC)

PMID35621299 (opens in a new tab)PMCIDPMC10065783 (opens in a new tab)DOI10.5935/1518-0557.20220006 (opens in a new tab)PepBankPUB-35621299
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

ObjectiveTo compare the effect of Medroxyprogesterone acetate versus Gonadotropin releasing hormone antagonist for the prevention of premature luteinizing hormone (LH) surge in infertile hyper-responder women undergoing controlled ovarian stimulation for in vitro fertilization (IVF) /intracytoplasmic sperm injection (ICSI) cycles.MethodsOne hundred infertile hyper-responder women who were candidate for IVF/ICSI were randomly assigned into two groups. Group 1 was given 20 mg Medroxyprogesterone acetate from day 1 of the menstrual cycle till trigger day. Group 2 was given GnRH antagonist (injection Cetrorelix 0.25 mg s/c) from the day when the leading follicle reached 14 mm until the day of trigger for the prevention of premature LH surge (flexible protocol). We measured LH serum levels on day 1, day 7 of cycle and on trigger day. The primary outcome measured was the incidence of premature LH surge. Other outcome measures were total number of mature follicles on trigger day, total number of mature oocytes retrieved and number of good quality day-3 embryos.ResultsThere was no premature luteinizing hormone surge in both groups of our study. The mean number of follicles on trigger day, mean number of M2 oocytes retrieved and mean number of good quality day-3 embryos were comparable in both the groups, with no statistically significant difference.ConclusionsThe results of this study stated that MPA can be an effective alternative to GnRH antagonist for the prevention of premature LH surge in hyper-responder women undergoing COS for IVF. It is easy to use, widely available and cost-effective. It may establish a new regimen of ovarian stimulation using MPA as an oral alternative to GnRH antagonist treatment in hyper-responders.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In infertile hyper-responder women undergoing IVF/ICSI, neither cetrorelix nor medroxyprogesterone acetate groups had a premature LH surge.

    In plain wordsIn hyper-responder women undergoing IVF/ICSI, no premature LH surge occurred with cetrorelix or medroxyprogesterone acetate.

    Peptide
    Cetrorelix
    Outcome
    No significant changePremature LH surge
    Study

    n = 100

    Comparator
    Medroxyprogesterone acetate 20 mg
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg · subcutaneous · From leading follicle reaching 14 mm until trigger dayAs given in this study (human).

    Source sentences

    Summary
    There was no premature luteinizing hormone surge in both groups of our study.
    3 context sentences
    Summary · context
    The primary outcome measured was the incidence of premature LH surge.
    Summary · context
    One hundred infertile hyper-responder women who were candidate for IVF/ICSI were randomly assigned into two groups.
    Summary · context
    Group 2 was given GnRH antagonist (injection Cetrorelix 0.25 mg s/c) from the day when the leading follicle reached 14 mm until the day of trigger for the prevention of premature LH surge (flexible protocol).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In infertile hyper-responder women, follicle, M2 oocyte, and good quality day-3 embryo numbers did not differ significantly between cetrorelix and medroxyprogesterone acetate.

    In plain wordsIn hyper-responder women, follicle, mature oocyte, and good quality embryo numbers did not differ significantly between cetrorelix and medroxyprogesterone acetate.

    Peptide
    Cetrorelix
    Outcome
    No significant changeFollicles, mature oocytes, and good quality embryos
    Study

    n = 100

    Comparator
    Medroxyprogesterone acetate 20 mg
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg · subcutaneous · From leading follicle reaching 14 mm until trigger dayAs given in this study (human).

    Source sentences

    Summary
    The mean number of follicles on trigger day, mean number of M2 oocytes retrieved and mean number of good quality day-3 embryos were comparable in both the groups, with no statistically significant difference.
    2 context sentences
    Summary · context
    One hundred infertile hyper-responder women who were candidate for IVF/ICSI were randomly assigned into two groups.
    Summary · context
    Group 2 was given GnRH antagonist (injection Cetrorelix 0.25 mg s/c) from the day when the leading follicle reached 14 mm until the day of trigger for the prevention of premature LH surge (flexible protocol).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.